英科医疗(300677) - 2023 Q3 - 季度财报

Financial Position - As of September 30, 2023, current assets totaled CNY 14,084,018,336, an increase of 37.3% from CNY 10,235,292,591 on January 1, 2023[1] - Cash and cash equivalents rose to CNY 6,785,382,296, up from CNY 5,033,125,320, reflecting a growth of 34.8%[1] - Trade receivables increased to CNY 875,183,820, a 58.3% rise compared to CNY 553,514,587 at the beginning of the year[1] - Total liabilities reached CNY 8,957,615,081, marking a significant increase from CNY 5,429,493,543[4] - Short-term borrowings surged to CNY 5,260,556,714, compared to CNY 1,494,006,760, indicating a growth of 252.5%[4] - Non-current assets amounted to CNY 11,142,911,677, slightly down from CNY 11,243,456,228[1] - The total equity attributable to shareholders increased to CNY 16,001,983,834 from CNY 15,806,329,512, reflecting a growth of 1.2%[4] - The total assets of the company reached CNY 25,226,930,013, up from CNY 21,478,748,819, representing a growth of 17.5%[4] Operating Performance - Total operating revenue for the current period is $5,041,996,590, a decrease of 3.27% from $5,212,259,481 in the previous period[8] - Total operating costs increased to $4,798,966,381, up 7.03% from $4,483,675,145 in the previous period[8] - Net profit for the current period is $337,256,744, down 46.32% from $632,878,360 in the previous period[9] - Basic and diluted earnings per share are both $0.50, compared to $0.97 in the previous period[9] - The company reported a significant increase in investment income to $78,201,382 from $29,933,159 in the previous period[8] - The company reported a decrease in inventory to CNY 919,633,825 from CNY 1,003,908,776, a decline of 8.4%[1] Cash Flow - Cash and cash equivalents at the end of the period increased to $6,618,931,458, up from $6,322,815,189 in the previous period[14] - The net cash flow from financing activities for the current period is $3,518,243,351, compared to a net outflow of $436,654,506 in the previous period[14] - The net cash flow from operating activities for the year-to-date period was CNY 221,801,184, down 82.81% year-over-year[21] - The company reported a net cash outflow from investing activities of CNY -2,327,090,815, compared to a net inflow of CNY 99,471,862 in the previous year[21] - Financing activities generated a net cash inflow of RMB 3,518,243,351, an increase of 905.73% compared to a net outflow of RMB 436,654,506 in the same period last year[41] Shareholder Information - The company has repurchased a total of 3,194,520 shares, accounting for 0.4848% of the total share capital, with a total transaction amount of RMB 69,578,168.60[35] - The company plans to use between RMB 100 million and RMB 200 million for share repurchase to implement employee stock ownership plans and/or equity incentives[35] - The total number of common shareholders at the end of the reporting period was 62,118[45] - Liu Fangyi holds 35.09% of shares, totaling 231,221,607 shares[45] - The total number of restricted shares at the beginning of the period was 183,453,513, with 2,225,642 shares released during the period[47] - The total number of shares held by executives at the end of the period was 142,935,184[47] - The company has a total of 7,125,462 shares remaining under the equity incentive lock-up plan[47] - The company has not disclosed any related party relationships among the top shareholders[45] - The company has not indicated any participation in margin trading by the top ten shareholders[45] Investment Activities - The company participated in an investment fund with its own funds amounting to 10 million RMB[49] - The company has completed the private fund registration procedures for the investment fund[49]